Brendan P. Halloran

Clinical, endoscopic and radiographic outcomes with ustekinumab in medically‐refractory Crohn's disease: real world experience from a multicentre cohort

Christopher Ma, Richard N. Fedorak, Gilaad G. Kaplan et al. · Alimentary Pharmacology & Therapeutics · 2017 · 182 citations · Full text

Metagenomic Analysis of Microbiome in Colon Tissue from Subjects with Inflammatory Bowel Diseases Reveals Interplay of Viruses and Bacteria

Weiwei Wang, Juan Jovel, Brendan P. Halloran et al. · Inflammatory Bowel Diseases · 2015 · 121 citations · Full text

Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohnʼs Disease

Christopher Ma, Richard N. Fedorak, Gilaad G. Kaplan et al. · Inflammatory Bowel Diseases · 2017 · 119 citations · Full text

Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn’s Disease: The Toronto Consensus

A. Hillary Steinhart, Remo Panaccione, Laura E. Targownik et al. · Inflammatory Bowel Diseases · 2018 · 103 citations · Full text

Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab

Anne Hu, Paulo Gustavo Kotze, Alice Burgevin et al. · Clinical Gastroenterology and Hepatology · 2020 · 87 citations

Systemic Treatment, Combination Therapy Does, Gastroenterology +5